Search | Clinical Trials Finder

Conditions: Substance Use, HIV Prevention
Interventions: LINKED, Group Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York

Conditions: HIV Infections
Interventions: rgp120/HIV-1IIIB, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 3
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Human Immunodeficiency Virus (HIV) Prophylaxis
Interventions: TDF IVR, TDF-FTC IVR, TDF-FTC-MVC IVR; Drug
Lead sponsor: Auritec Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: HIV Infections
Interventions: chloroquine phosphate, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more

Conditions: HIV Infections
Interventions: Project ABLE; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Risk Perception, PrEP
Interventions: Multi-component intervention strategy; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 145
States / cities: Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more

Conditions: HIV Infection
Interventions: Tenofovir DF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Video consent (high-tech), Video consent (low-tech), FAQ format consent, Standard consent, PDF informed consent document; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 2,405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: No intervention; Observational study; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more

Conditions: HIV
Interventions: NIATx + ECHO; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: West Conshohocken, Pennsylvania

Conditions: HIV Disease
Interventions: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Use of creatine monohydrate (a dietary supplement), Progressive resistance exercise training; Procedure · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Microbicide Delivery System Perceptibility and Acceptability
Interventions: Gel, Suppository 1, Suppository 2; Other
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV-1 Infection
Interventions: 3BNC117, Antiretroviral Treatment Interruption; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Delavirdine mesylate, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 10
States / cities: Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Lymphoma
Interventions: RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Systemix; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 2 more

Conditions: HIV Infections, AIDS
Interventions: raltegravir, efavirenz; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Sacramento, California

Conditions: Smoking Cessation
Interventions: Self-help materials, nicotine patch, Counseling, Smartphone-delivered automated treatment; Behavioral · Drug · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: HIV Infections
Interventions: sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571, 3M-052-AF, Alum; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts

Conditions: HIV Infections
Interventions: Camino Intervention; Behavioral
Lead sponsor: American University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Berkeley, California • Washington D.C., District of Columbia

Conditions: Self-management
Interventions: Social justice Oriented, Family-Informed self-management intervention for APAWH (SOFIAA); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Search by objective public record fields.

A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Culturally-Tailored HIV Risk Reduction for African-American MSM

A Multicomponent Intervention to Increase HIV Risk Perceptions and PrEP Initiation Among Black Men Who Have Sex With Men

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Tenofovir Disoproxil Fumarate to Treat Pediatric HIV

Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

Peru Decentralized HIV Care

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

Effects of Creatine and Resistance Exercise Training in People With HIV Infection

Developing Rectal USPE Measures for Suppositories (Project DRUM-S)

A Study of the Safety and Antiretroviral Activity of 3BNC117

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Smartphone-delivered Automated Video-assisted Smoking Treatment for People Living With HIV

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

El Camino HIV Prevention and Care Study

Testing a Self-management Intervention in HIV+ Asian Pacific Americans